Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Parexel Recognized as Most Favored Provider in ISR CRO Phase I Quality Benchmarking Report | ||
| By: GlobeNewswire - 13 May 2021 | Back to overview list |
|
Recognition marks fourth consecutive year as top-ranked Phase I provider to work with; Company ranked among top-two global CROs for Service Provider Leadership, Familiarity, Use and Preference in Phase I BOSTON and DURHAM, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance world health, today announced it ranked as the Most Favored Provider for Phase I services in a new report released May 10 by Industry Standard Research (ISR). Parexel was one of two CROs to garner the highest scores across Service Provider Leadership, Familiarity, Use and Preference in Phase I services. ISR’s report, titled “Phase I CRO Benchmarking (13th Edition)” surveyed 191 biopharmaceutical professionals and 500 service provider encounters across North America, Europe and Asia, evaluating 40 CROs on 22 attributes across five categories (Budget Factors, Delivery Factors, Staff Characteristics, Accessibility and Services). “This recognition is a testament to our colleagues around the world and the passion and expertise they bring to their work every day,” said Jamie Macdonald, CEO. “This past year has challenged all of us in the industry to bring our best to the drug development process and to find new and innovative ways to help patients. Our performance in the ISR survey underscores our deep commitment to putting patients at the heart of everything we do.” About Parexel Media Contact: |
||
|
|
||
 | Back to overview list | |